Wave Life Sciences have announced the disappointing news that the development of the drug suvodirsen for DMD has been discontinued.
They shared that the exon skipping drug did not ‘restore meaningful levels of dystrophin’ in people with DMD. Wave plan to share additional findings, which may inform future research.
For more information, read Wave Life Sciences Press Release
Previous news related to this story:
28 June 2019
Wave Life Sciences has announced that it has started a global Phase 2/3 clinical trial testing suvodirsen in boys with DMD. Suvodirsen is an exon-skipping drug that aims to increase the levels of dystrophin protein in muscles. The trial, named DYSTANCE 51, will enrol boys who are between 5 and 12 years of age, still walking and amenable to exon 51 skipping. The trial will include sites in the US, Europe, Australia, Canada and Japan.
For more information, read Wave’s press release.
16 April 2019
Wave Life Sciences has shared details of its upcoming Phase II/III clinical trial testing suvodirsen in boys with DMD. Suvodirsen is an exon-skipping drug that targets exon 51 within the dystrophin gene. The study, named DYSTANCE 51, will start in July 2019 and enrol boys who are between 5 and 12 years of age. Participants will receive suvodirsen or placebo once a week for 48 weeks.
For further information, please read Wave’s press release.